Hormone Replacement Therapy: What the FDA's Updated Guidance Means for Women

For more than two decades, many women avoided hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT), because of concerns about heart disease, breast cancer, stroke, and dementia. Those concerns largely stemmed from the Women's Health Initiative (WHI) study published in 2002, which dramatically changed how hormone therapy was viewed and prescribed.

Today, the science tells a much more complete story.

After reviewing decades of additional research, the U.S. Food and Drug Administration (FDA) has updated the labeling of menopausal hormone therapy products, removing outdated boxed ("black box") warnings for several products and replacing them with guidance that better reflects current evidence. The change recognizes what menopause specialists have been saying for years: for most healthy women younger than 60 years old or within 10 years of menopause, the benefits of hormone therapy generally outweigh the risks when used appropriately (FDA, 2026).

Why Was HRT Considered Dangerous?

The concern surrounding HRT began after the Women's Health Initiative (WHI) released preliminary findings in 2002. Early reports suggested increased risks of:

• Breast cancer

• Heart disease

• Stroke

• Blood clots

• Dementia

The headlines caused millions of women to stop hormone therapy almost overnight, and physicians became far more hesitant to prescribe it.

However, one critical detail was often overlooked.

The average participant in the WHI study was approximately 63 years old, meaning many women began hormone therapy well after menopause, when cardiovascular disease risk naturally increases. Researchers have since learned that timing matters (Manson et al., 2024).

What We Know Today

Over the past 20 years, researchers have continued to analyze WHI data and conduct additional studies. The evidence now consistently shows that women who begin hormone therapy:

• Before age 60

• Or within 10 years of menopause

generally experience a favorable benefit-risk profile when there are no major contraindications.

Hormone therapy remains the most effective treatment available for:

• Hot flashes

• Night sweats

• Sleep disruption

• Vaginal dryness

• Painful intercourse

• Prevention of menopause-related bone loss and osteoporosis

The North American Menopause Society, the American College of Obstetricians and Gynecologists (ACOG), and other leading medical organizations have supported this position for several years, and the FDA's recent labeling updates now better align with that scientific consensus.

The FDA's Updated Position

Following a comprehensive review of modern evidence, the FDA approved labeling changes removing boxed warning statements related to:

• Cardiovascular disease

• Breast cancer

• Probable dementia

from several menopausal hormone therapy products.

The FDA now recommends that systemic hormone therapy generally be considered for women who are:

• Younger than 60 years of age, or

• Within 10 years of menopause onset,

when the benefits outweigh the potential risks for the individual patient. Treatment decisions should always be personalized through shared decision-making between a woman and her healthcare provider (FDA, 2026).

Who May Benefit from Hormone Therapy?

Hormone therapy may be appropriate for women experiencing moderate to severe menopausal symptoms, including:

• Frequent hot flashes

• Night sweats

• Sleep disturbances

• Mood changes related to menopause

• Vaginal dryness

• Pain during intercourse

• Accelerated bone loss

Many women also report significant improvements in:

• Overall quality of life

• Energy levels

• Sexual health

• Daily functioning

• Sleep quality

The goal of therapy is not simply to relieve symptoms but to help women maintain health and function during the menopausal transition.

Individualized Care Matters

Modern menopause care has moved away from a "one-size-fits-all" approach.

Today's providers evaluate:

• Age

• Time since menopause

• Medical history

• Family history

• Cardiovascular risk

• Personal treatment goals

• Type and severity of symptoms

Hormone therapy may include:

• Estrogen alone (for women without a uterus)

• Estrogen combined with progesterone (for women with an intact uterus)

• Oral medications

• Transdermal patches

• Topical gels

• Vaginal estrogen preparations

Selecting the appropriate formulation helps maximize benefits while minimizing potential risks.

The Bottom Line

The FDA's updated labeling reflects an important shift toward evidence-based menopause care.

While hormone therapy is not appropriate for every woman, current research supports that for most healthy women younger than 60 or within 10 years of menopause, hormone therapy is both safe and highly effective for managing menopausal symptoms when prescribed appropriately.

If menopause symptoms are affecting your quality of life, don't let outdated information prevent you from exploring your options. A conversation with a knowledgeable healthcare provider can help determine whether hormone therapy is right for you.

At Hormone Treatment Centers, we provide personalized evaluations and evidence-based treatment plans to help women navigate menopause safely and confidently.

Works Cited

Food and Drug Administration. (2026, February 12). FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

Food and Drug Administration. (2025). HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy

Harvard Health Publishing. (2025). FDA Removes Menopause Hormone Therapy Black Box Warnings. Harvard Medical School. https://www.health.harvard.edu/womens-health/fda-removes-menopause-hormone-therapy-black-box-warnings

U.S. Department of Health and Human Services. (2025). HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. https://www.hhs.gov/press-room/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy.html